Pharmaceutical - Pharmaceutical, UCB

Filter

Current filters:

PharmaceuticalUCB

Popular Filters

1 to 25 of 62 results

Latest Ph III data for UCB’s brivaracetam presented at AES

Latest Ph III data for UCB’s brivaracetam presented at AES

08-12-2014

Positive primary efficacy and safety data from the latest Phase III study evaluating Belgian drugmaker…

BRIVARACETAMNeurologicalPharmaceuticalResearchUCB

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

28-11-2014

Japanese drug major Daiichi Sankyo and Belgian drugmaker UCB have entered into an agreement to jointly…

Daiichi SankyoJapanlacosamide Tablet and InjectionLicensingNeurologicalPharmaceuticalUCBVimpat

UCB calls upon UK government for greater incentives for industry partnering

UCB calls upon UK government for greater incentives for industry partnering

29-10-2014

Belgian drugmaker UCB has called for further collaboration in life sciences to enhance drug discovery…

PharmaceuticalResearchUCBUKUnited Kingdom

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

30-09-2014

Belgian drugmaker UCB has launched an awareness-raising campaign around brain-related illnesses such…

EuropeNeurologicalPharmaceuticalSocial IssuesUCB

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

UCB expands access to clinical trial data

UCB expands access to clinical trial data

01-08-2014

Belgian drugmaker UCB is now part of the Multi-Sponsor Environment, allowing for the responsible sharing…

BelgiumClinical researchPharmaceuticalResearchUCB

UCB reports solid 1st-half performance

UCB reports solid 1st-half performance

31-07-2014

Belgian drugmaker UCB posted first-half 2014 revenue of 1.76 billion euros ($2.36 billion), plus 6%,…

BelgiumChemistryChief executiveEURFinancialOrganic chemistryPharmaceuticalUCBVimpat

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

EIB and UCB partner to accelerate development of new medicines

EIB and UCB partner to accelerate development of new medicines

17-06-2014

The European Investment Bank (EIB), the financing institution of the European Union, has signed an agreement…

EuropeFinancialPharmaceuticalResearchUCB

UCB celebrates 10 years of investment in the UK since acquiring Celltech

UCB celebrates 10 years of investment in the UK since acquiring Celltech

02-06-2014

Belgian drugmaker UCB is today celebrating 10 years presence in the UK, following the company’s acquisition…

Business FinanceCelltechPharmaceuticalPharmaceutical sciencesUCBUK

UCB enters strategic alliance with Weill-Cornell in three discovery projects

03-04-2014

Belgian drugmaker UCB has launched a major, three-year strategic research alliance with Weill-Cornell…

MetabolicsPharmaceuticalRare diseasesResearchUCB

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Core products boost UCB 2013 sales, but profits disappoint

26-02-2014

Belgium’s largest drugmaker UCB this morning reported financial results for 2013, with gross profit…

FinancialPharmaceuticalUCB

UCB CEO succession plan ahead of next wave of product launches

UCB CEO succession plan ahead of next wave of product launches

21-02-2014

Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch…

BoardroomManagementPharmaceuticalUCB

UCB links with UK’s MRC Technology for a fibrosis program

UCB links with UK’s MRC Technology for a fibrosis program

13-02-2014

Belgium’s leading drugmaker UCB and UK’s MRC Technology have entered an exclusive license agreement,…

LicensingPharmaceuticalResearchUCB

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

UCB launches online search for rare phenotypes

UCB launches online search for rare phenotypes

28-01-2014

Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an online search to find rare phenotypes…

GeneticsGlobalPharmaceuticalRare diseasesResearchUCB

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

1 to 25 of 62 results

Back to top